HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brousseau, M. E. Articles by Hoeg, J. M. Search for Related Content PubMed PubMed Citation Articles by Brousseau, M. E. Articles by Hoeg, J. M. Social Bookmarking                      What's this?

The Journal of Lipid Research, Vol. 40, 365-375, March 1999
Copyright © 1999 by Lipid Research, Inc.

Review

Transgenic rabbits as models for atherosclerosis research

Correspondence to: Margaret E. Brousseau

Several characteristics of the rabbit make it an excellent model for the study of lipoprotein metabolism and atherosclerosis. New Zealand White (NZW) rabbits have low plasma total cholesterol concentrations, high cholesteryl ester transfer protein activity, low hepatic lipase (HL) activity, and lack an analogue of human apolipoprotein (apo) A-II, providing a unique system in which to assess the effects of human transgenes on plasma lipoproteins and atherosclerosis susceptibility. Additionally, rabbit models of human lipoprotein disorders, such as the Watanabe Heritable Hyperlipidemic (WHHL) and St. Thomas' Hospital strains, models of familial hypercholesterolemia and familial combined hyperlipidemia, respectively, allow for the assessment of candidate genes for potential use in the treatment of dyslipoproteinemic patients. To date, transgenes for human apo(a), apoA-I, apoB, apoE₂, apoE₃, HL, and lecithin:cholesterol acyltransferase (LCAT), as well as for rabbit apolipoprotein B mRNA-editing enzyme catalytic poly-peptide 1 (APOBEC-1), have been expressed in NZW rabbits, whereas only those for human apoA-I and LCAT have been introduced into the WHHL background. All of these transgenes have been shown to have significant effects on plasma lipoprotein concentrations. In both NZW and WHHL rabbits, human apoA-I expression was associated with a significant reduction in the extent of aortic atherosclerosis, which was similarly the case for LCAT in rabbits having at least one functional LDL receptor allele. Conversely, expression of apoE₂ in NZW rabbits caused increased susceptibility to atherosclerosis. These studies provide new insights into the mechanisms responsible for the development of atherosclerosis, emphasizing the strength of the rabbit model in cardiovascular disease research.—Brousseau, M. E., and J. M. Hoeg. Transgenic rabbits as models for atherosclerosis research. J. Lipid Res. 1999. 40: 365–375.

Supplementary key words: apolipoproteins, atherosclerosis, lipid enzymes, transgenic, New Zealand White, Watanabe Heritable Hyperlipidemic

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J.-P. P. de Barros, A. Boualam, T. Gautier, L. Dumont, B. Verges, D. Masson, and L. Lagrost Apolipoprotein CI is a physiological regulator of cholesteryl ester transfer protein activity in human plasma but not in rabbit plasma J. Lipid Res., September 1, 2009; 50(9): 1842 - 1851. [Abstract] [Full Text] [PDF]

				T. Kawai, T. Ito, K. Ohwada, Y. Mera, M. Matsushita, and H. Tomoike Hereditary Postprandial Hypertriglyceridemic Rabbit Exhibits Insulin Resistance and Central Obesity: A Novel Model of Metabolic Syndrome Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2752 - 2757. [Abstract] [Full Text] [PDF]

				M. Rahmani, R. P. Cruz, D. J. Granville, and B. M. McManus Allograft Vasculopathy Versus Atherosclerosis Circ. Res., October 13, 2006; 99(8): 801 - 815. [Abstract] [Full Text] [PDF]

				S. Acin, M. A. Navarro, J. M. Arbones-Mainar, N. Guillen, A. J. Sarria, R. Carnicer, J. C. Surra, I. Orman, J. C. Segovia, R. d. l. Torre, et al. Hydroxytyrosol Administration Enhances Atherosclerotic Lesion Development in Apo E Deficient Mice J. Biochem., September 1, 2006; 140(3): 383 - 391. [Abstract] [Full Text] [PDF]

				J. M. Arbones-Mainar, M. A. Navarro, S. Acin, M. A. Guzman, C. Arnal, J. C. Surra, R. Carnicer, H. M. Roche, and J. Osada Trans-10, cis-12- and cis-9, trans-11-Conjugated Linoleic Acid Isomers Selectively Modify HDL-Apolipoprotein Composition in Apolipoprotein E Knockout Mice J. Nutr., February 1, 2006; 136(2): 353 - 359. [Abstract] [Full Text] [PDF]

				M. Rizzo, J. M. Taylor, C. M. Barbagallo, K. Berneis, P. J. Blanche, and R. M. Krauss Effects on Lipoprotein Subclasses of Combined Expression of Human Hepatic Lipase and Human apoB in Transgenic Rabbits Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 141 - 146. [Abstract] [Full Text] [PDF]

				M. Shiomi, T. Ito, S. Yamada, S. Kawashima, and J. Fan Development of an Animal Model for Spontaneous Myocardial Infarction (WHHLMI Rabbit) Arterioscler Thromb Vasc Biol, July 23, 2003; 23(7): 1239 - 1244. [Abstract] [Full Text] [PDF]

				J. Fan, H. Unoki, N. Kojima, H. Sun, H. Shimoyamada, H. Deng, M. Okazaki, H. Shikama, N. Yamada, and T. Watanabe Overexpression of Lipoprotein Lipase in Transgenic Rabbits Inhibits Diet-induced Hypercholesterolemia and Atherosclerosis J. Biol. Chem., October 19, 2001; 276(43): 40071 - 40079. [Abstract] [Full Text] [PDF]